Lv1
36 积分 2021-11-18 加入
[Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer]
15小时前
已完结
Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study
18小时前
已完结
Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence
12天前
已完结
Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
13天前
已完结
Breast Cancer Treatment
14天前
已完结
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
14天前
已完结
Management of Metastatic Hormone Receptor-Positive Breast Cancer Beyond CDK4/6 Inhibitors
16天前
已完结
Comprehensive safety assessment of ribociclib: A real‐world analysis using the FDA Adverse Event Reporting System (FAERS) database
20天前
已完结
Myasthenia Gravis With Acetylcholine Receptor Antibodies in the Very Old: Treatment Challenges and Diagnostic Pitfalls
25天前
已完结
High expression of IRF8 in AChR-specific cells regulates the function of B cells
25天前
已关闭
皖公网安备34019202002308
